Annual ROE
-47.57%
-12.85%-37.01%
December 31, 2023
Summary
- As of February 8, 2025, OVID annual return on equity is -47.57%, with the most recent change of -12.85% (-37.01%) on December 31, 2023.
- During the last 3 years, OVID annual ROE has risen by +95.03% (+66.64%).
- OVID annual ROE is now -143.25% below its all-time high of 109.98%, reached on December 31, 2021.
Performance
OVID ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-37.57%
-5.72%-17.96%
September 30, 2024
Summary
- As of February 8, 2025, OVID quarterly return on equity is -37.57%, with the most recent change of -5.72% (-17.96%) on September 30, 2024.
- Over the past year, OVID quarterly ROE has increased by +9.75% (+20.60%).
- OVID quarterly ROE is now -129.31% below its all-time high of 128.18%, reached on March 31, 2021.
Performance
OVID Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
OVID ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -37.0% | +20.6% |
| 3 y3 years | +66.6% | +20.6% |
| 5 y5 years | +64.5% | +20.6% |
OVID ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -143.3% | at low | -151.9% | +26.0% |
| 5 y | 5-year | -143.3% | +66.6% | -129.3% | +78.1% |
| alltime | all time | -143.3% | +66.6% | -129.3% | +78.1% |
Ovid Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -37.57%(+18.0%) |
| Jun 2024 | - | -31.85%(-37.3%) |
| Mar 2024 | - | -50.78%(+7.3%) |
| Dec 2023 | -47.57%(+37.0%) | -47.32%(+18.4%) |
| Sep 2023 | - | -39.95%(+6.8%) |
| Jun 2023 | - | -37.41%(+3.7%) |
| Mar 2023 | - | -36.09%(+2.8%) |
| Dec 2022 | -34.72%(-131.6%) | -35.12%(-14.5%) |
| Sep 2022 | - | -41.07%(+8.7%) |
| Jun 2022 | - | -37.80%(+5.8%) |
| Mar 2022 | - | -35.73%(-149.3%) |
| Dec 2021 | 109.98%(-177.1%) | 72.41%(-16.4%) |
| Sep 2021 | - | 86.60%(-19.6%) |
| Jun 2021 | - | 107.65%(-16.0%) |
| Mar 2021 | - | 128.18%(-174.8%) |
| Dec 2020 | -142.60% | -171.32%(+21.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | -140.96%(-15.8%) |
| Jun 2020 | - | -167.44%(+23.6%) |
| Mar 2020 | - | -135.45%(+13.6%) |
| Dec 2019 | -86.34%(-35.5%) | -119.28%(-9.3%) |
| Sep 2019 | - | -131.50%(+19.4%) |
| Jun 2019 | - | -110.14%(+8.4%) |
| Mar 2019 | - | -101.57%(+8.4%) |
| Dec 2018 | -133.95%(+72.5%) | -93.67%(+24.8%) |
| Sep 2018 | - | -75.08%(+25.1%) |
| Jun 2018 | - | -60.00%(+19.8%) |
| Mar 2018 | - | -50.08%(-38.2%) |
| Dec 2017 | -77.67%(+70.8%) | -81.09%(-5.7%) |
| Sep 2017 | - | -86.03%(-4.5%) |
| Jun 2017 | - | -90.10%(-22.1%) |
| Mar 2017 | - | -115.62%(+154.3%) |
| Dec 2016 | -45.47%(+135.2%) | -45.47% |
| Dec 2015 | -19.33% | - |
FAQ
- What is Ovid Therapeutics annual return on equity?
- What is the all time high annual ROE for Ovid Therapeutics?
- What is Ovid Therapeutics annual ROE year-on-year change?
- What is Ovid Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Ovid Therapeutics?
- What is Ovid Therapeutics quarterly ROE year-on-year change?
What is Ovid Therapeutics annual return on equity?
The current annual ROE of OVID is -47.57%
What is the all time high annual ROE for Ovid Therapeutics?
Ovid Therapeutics all-time high annual return on equity is 109.98%
What is Ovid Therapeutics annual ROE year-on-year change?
Over the past year, OVID annual return on equity has changed by -12.85% (-37.01%)
What is Ovid Therapeutics quarterly return on equity?
The current quarterly ROE of OVID is -37.57%
What is the all time high quarterly ROE for Ovid Therapeutics?
Ovid Therapeutics all-time high quarterly return on equity is 128.18%
What is Ovid Therapeutics quarterly ROE year-on-year change?
Over the past year, OVID quarterly return on equity has changed by +9.75% (+20.60%)